Celerion’s clinical trial design is creative, strategic and consultative, and we do it well. The advantages of our adaptive and innovative study designs are to decrease overall time, cost and risk in the development program. All aspects of your study are taken into consideration so that you will have the right data at the right decision points. With adaptive designs, early results may affect aspects of the final study design itself. Celerion has the technology and capability to ensure that your data is accurate and easily accessible when you need it. Additionally, through our extensive site networks, we can address any unique issues or considerations in treating or retaining your target patient population. With a close focus on inclusion/exclusion (I/E) criteria, we can facilitate quick enrollment and/or patient recruitment risk mitigation.
By leveraging Celerion’s industry-leading first-in-human capabilities, our clients can move seamlessly through first-in-patient and clinical proof-of-concept studies to determine if the new drug candidate is working in humans as planned. Celerion adds significant value to your program through the combination of our operational skills, specialist procedures and access to clinical expertise and patients. Your design must be robust enough to ensure that you have the data that you think you’ll need to answer the questions for critical go, no-go decisions. Our goal is to proactively instill risk mitigation strategies into your study plan.
Full Service Global Clinical Development
Celerion, a full-service, early clinical CRO, is the leader in accelerating development for Phase I-IIb. Our unique combination of medical expertise, clinical operations experience and scientific excellence, enables you to make timely decisions with expert advice and high-quality data. Our leadership in clinical pharmacology through Proof-of-Concept is focused on helping you translate your science to medicine.